← Back to Search

Monoclonal Antibodies

clazakizumab at a dose of 25 mg for Coronavirus

Phase 2
Recruiting
Led By Nada Alachkar, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 days
Awards & highlights

Study Summary

This trial will test if the drug clazakizumab can help treat patients with severe COVID-19. 30 patients will be given the drug or a placebo and researchers will compare the results.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in C-reactive protein (CRP) level

Side effects data

From 2015 Phase 2 trial • 143 Patients • NCT02015520
5%
HYPERURICAEMIA
5%
BRONCHITIS
5%
INJECTION SITE RASH
5%
HYPERTRIGLYCERIDAEMIA
5%
COUGH
5%
INJECTION SITE BRUISING
5%
INFLUENZA LIKE ILLNESS
5%
CONTUSION
5%
FATIGUE
5%
URINARY TRACT INFECTION
5%
HYPERCHOLESTEROLAEMIA
100%
80%
60%
40%
20%
0%
Study treatment Arm
Clazakizumab (1 mg) + MTX
Clazakizumab (25 mg) + MTX
Clazakizumab (5 mg) + MTX
Placebo + Methotrexate (MTX)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: clazakizumab at a dose of 25 mgExperimental Treatment1 Intervention
A first dose of 25 mg of clazakizumab will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25mg clazakizumab (an identical dose to the day 1 dose) will be given no later than day 3
Group II: placeboPlacebo Group1 Intervention
A first dose of placebo will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo (an identical dose to the day 1 dose) will be given no later than day 3
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clazakizumab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,274 Previous Clinical Trials
14,840,487 Total Patients Enrolled
Nada Alachkar, MDPrincipal InvestigatorJohns Hopkins University
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top